INNOVATION IN THE MEDICAL TREATMENT Of PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND INOPERABLE, PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: SOLUBLE GUANILATE CYCLASE STIMULATOR – RIOCIGUAT
https://doi.org/10.17802/2306-1278-2016-4-87-95
Abstract
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are diseases, diagnosed at a late stage with functional class III or IV according to World health organization (WHO). PAH and CTEPH leads to severe right heart failure
and ultimately, death. The modern researches aim at exploring the potential therapeutic targets, as at developing new drugs that can affect the previously set target. Riociguat is the first in a new class of soluble guanylatecyclase stimulators. The analysis of main researches, which reflect the evidence of riociguat efficiacy and safety in patients with PAH and inoperable, persistent/recurrent CTEPH, is presented in this rewiew.
About the Authors
I. N. TARAN
Federal State Budgetary Institution Russian Cardiology Research and Production Complex, Scientific research institute of clinical cardiology of A. L. Myasnikov;
Laboratory of a pulmonary hypertension, Department of a hypertension, Moscow, Russia
Russian Federation
Russian Federation
Address: 15A, 3-ya Cherepkovskaya st., Moscow, 121552, Russian Federation Tel.: +7-968-654-94-06
T. V. MARTYNUK
Federal State Budgetary Institution Russian Cardiology Research and Production Complex, Scientific research institute of clinical cardiology of A. L. Myasnikov;
Laboratory of a pulmonary hypertension, Department of a hypertension, Moscow, Russia
Russian Federation
Russian Federation
S. N. NAKONECHNIKOV
Federal State Budgetary Institution Russian Cardiology Research and Production Complex, Scientific research institute of clinical cardiology of A. L. Myasnikov;
Laboratory of a pulmonary hypertension, Department of a hypertension, Moscow, Russia
Russian Federation
Russian Federation
I. E. CHAZOVA
Federal State Budgetary Institution Russian Cardiology Research and Production Complex, Scientific research institute of clinical cardiology of A. L. Myasnikov;
Laboratory of a pulmonary hypertension, Department of a hypertension, Moscow, Russia
Russian Federation
Russian Federation
References
1. Galie N., Hoeper M. M., Humbert M., Torbicki A., Vachiery J. L., Barbera J. A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur. Heart. J. 2009; 30 (20): 2493–2537. DOI: 10.1093/eurheartj/ehp297.
2. Kim N. H., Delcroix M., Jenkins D. P., Channick R., Dartevelle P., Jansa P. et al. Chronic Thromboembolic Pulmonary Hypertension. J. Am. Coll. Cardiol. 2013; 62 (Suppl): 92–99. DOI: 10.1016/j.jacc.2013.10.024.
3. Чазова И. Е., Мартынюк Т. В., Чернявский А. М., Мершин К. В., Данилов Н. М., Матчин Ю. Г. Федеральные клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии – 2015. Режим доступа: http://www.cardioweb.ru/klinicheskie-rekomendatsii. Chazova I. E., Martynyuk T. V., Chernyavskiy A. M., Mershin K. V., Danilov N. M., Matchin Yu. G. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu khronicheskoy tromboembolicheskoy legochnoy gipertenzii – 2015. [Internet]. Avaliable from: http://www.cardioweb.ru/klinicheskie-rekomendatsii.
4. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122: 156–163. DOI: 10.1161/CIRCULATIONAHA.109.911818.
5. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Riociguat (Adempas): Management of Inoperable Chronic Thromboembolic Pulmonary Hypertension; 2015 Jul.
6. Чазова И. Е., Авдеев С. Н., Царева Н. А., Мартынюк Т. В., Волков А. В., Наконечников С. Н. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив. 2014; 9: 4–23. Chazova I. E., Avdeev S. N., Tsareva N. A., Martynyuk T. V., Volkov A. V., Nakonechnikov S. N. Klinicheskie rekomendatsii po diagnostike i lecheniyu legochnoy gipertenzii. Terapevticheskiy arkhiv. 2014; 9: 4–23.
7. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995; 333: 214–221.
8. Stasch J. P., Pacher P., Evgenov O. V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011; 123: 2263–2273.
9. Leuchte H. H., Schwaiblmair M., Baumgartner R. A., Neurohr C. F., Kolbe T., Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004; 125: 580–586.
10. Mittendorf J., Weigand S., Alonso-Alija C., Bischoff E., Feurer A., Gerisch M. et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem. Med. Chem. 2009; 4: 853–865. DOI: 10.1002/cmdc.200900014.
11. Evgenov O. V., Ichinose F., Evgenov N. V., Gnoth M. J., Falkowski G. E. et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation. 2004; 110: 2253–2259.
12. Dumitrascu R., Weissmann N., Ghofrani H. A., Dony E., Beuerlein K. et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006; 113: 286–290.
13. Grimminger F., Weimann G., Frey R., Voswinckel R., Thamm M., Bölkow D. et al. First acute haemodynamic study of soluble guanylatecyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 2009; 33: 785–792. DOI: 10.1183/09031936.00039808.
14. Lang M., Kojonazarov B., Weissmann N., Grimminger F., Stasch J. P., Seeger W., Ghofrani H. A. et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. BMC Pharmacology. 2011; 11 (Suppl 1): 43.
15. Ghofrani H. A., Hoeper M. M., Halank M., Meyer F. J., Staehler G., Behr J., Ewert R. et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur. Respir. J. 2010; 36: 792–799. DOI: 10.1183/09031936.00182909.
16. Rubin L. J., Galiè N., Grimminger F., Grünig E., Humbert M., Jing Z. C. et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT- 2). Eur. Respir. J. 2015; 45 (5): 1303–1313.
17. Ghofrani H. A., Grimminger F., Grünig E., Huang Y., Jansa P., Jing Z. C. et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, longterm extension trial. The Lancet Respiratory Medicine. 2016; 2213–2600.
18. Simonneau G., D’Armini A. M., Ghofrani H. A., Grimminger F., Hoeper M. M., Jansa P., Kim N. H. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Europian Respiratory Journal. 2015; 45 (5): 1293–1302.
19. Minai O. A., Bonner N., Mathai S. C., Busse D., Brockmann B., Teal S. et al. Assessment Of Patient-Reported Health Status In Chronic Thromboembolic Pulmonary Arterial HypertensionPatients Treated With Riociguat: 2-Year Results From The Chest-2 Extension Study. Value Health. 2015; 18 (7): 398–399. DOI: 10.1016/j.jval.2015.09.911.
20. Hoeper M. M., McLaughlin V. V., Dalaan A. M., Satoh T., Galiè N. Treatment of pulmonary hypertension. Lancet Respir. Med. 2016; 4 (4): 323–336.
21. Simonneau G., D’Armini A. M., Ghofrani H. A., Grimminger F., Hoeper M. M., Jansaet P. et al. Latebreaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension [Internet]. European Respiratory Journal. 2014; 44 (Suppl 58). Avaliable from: http://erj.ersjournals.com/content/44/Suppl_58/P1802.
22. Hoeper M. M., Corris P. A., Kinger J. R., Langleben D., Naeije R., Simonneau G. et al. The RESPITE Study: Riociguat In Patients With PAH And An Inadequate Response To Phosphodiesterase 5 Inhibitors. Am. J. Crit. Care. Med. 2016; 193: 6315.
Review
For citations:
TARAN I.N., MARTYNUK T.V., NAKONECHNIKOV S.N., CHAZOVA I.E. INNOVATION IN THE MEDICAL TREATMENT Of PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND INOPERABLE, PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: SOLUBLE GUANILATE CYCLASE STIMULATOR – RIOCIGUAT. Complex Issues of Cardiovascular Diseases. 2016;(4):87-95. (In Russ.) https://doi.org/10.17802/2306-1278-2016-4-87-95
Views:
543
